HomepageIMM • ASX
add
Immutep Ltd
Vorige slotkoers
$Â 0,42
Dag-range
$Â 0,42 - $Â 0,44
Jaar-range
$Â 0,22 - $Â 0,44
Beurswaarde
611,59Â mln. AUD
Gem. volume
4,29Â mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
ASX
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (AUD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 948,05K | 9,53% |
Bedrijfskosten | 2,21Â mln. | 8,90% |
Netto inkomsten | -19,53Â mln. | -81,76% |
Netto winstmarge | -2,06K | -65,94% |
Winst per aandeel | — | — |
EBITDA | -18,24Â mln. | -62,71% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (AUD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 129,69Â mln. | -28,69% |
Totale activa | 156,98Â mln. | -22,12% |
Totale passiva | 13,35Â mln. | 10,70% |
Totaal aandelenvermogen | 143,64 mln. | — |
Uitstaande aandelen | 1,47 mld. | — |
Koers-boekwaardeverhouding | 4,15 | — |
Rendement op activa | -30,73% | — |
Rendement op kapitaal | -33,21% | — |
Kasstroom
Nettomutatie in liquide middelen
| (AUD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -19,53Â mln. | -81,76% |
Operationele kasstroom | -16,75Â mln. | -104,65% |
Kasstroom uit beleggingen | 12,14Â mln. | 217,88% |
Kasstroom uit financiering | -48,98K | -100,10% |
Nettomutatie in liquide middelen | -3,24Â mln. | -111,16% |
Vrije kasstroom | -10,32Â mln. | -84,32% |
Over
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
CEO
Opgericht
2001
Website
Werknemers
19
